Genomics of chromophobe renal cell carcinoma: implications from a rare tumor for pan-cancer studies

Chromophobe Renal Cell Carcinoma (ChRCC) is a rare subtype of the renal cell carcinomas, a heterogenous group of cancers arising from the nephron. Recently, The Cancer Genome Atlas (TCGA) profiled this understudied disease using multiple data platforms, including whole exome sequencing, whole genome sequencing (WGS), and mitochondrial DNA (mtDNA) sequencing. The insights gained from this study would have implications for other types of kidney cancer as well as for cancer biology in general. Global molecular patterns in ChRCC provided clues as to this cancer's cell of origin, which is distinct from that of the other renal cell carcinomas, illustrating an approach that might be applied towards elucidating the cell of origin of other cancer types. MtDNA sequencing revealed loss-of-function mutations in NADH dehydrogenase subunits, highlighting the role of deregulated metabolism in this and other cancers. Analysis of WGS data led to the discovery of recurrent genomic rearrangements involving TERT promoter region, which were associated with very high expression levels of TERT, pointing to a potential mechanism for TERT deregulation that might be found in other cancers. WGS data, generated by large scale efforts such as TCGA and the International Cancer Genomics Consortium (ICGC), could be more extensively mined across various cancer types, to uncover structural variants, mtDNA mutations, themes of tumor metabolic properties, as well as noncoding point mutations. TCGA's data on ChRCC should continue to serve as a resource for future pan-cancer as well as kidney cancer studies, and highlight the value of investigations into rare tumor types to globally inform principals of cancer biology.

[1]  Hiromi Nakamura,et al.  Trans-ancestry mutational landscape of hepatocellular carcinoma genomes , 2014, Nature Genetics.

[2]  E. Larsson,et al.  Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types , 2014, Nature Genetics.

[3]  Lawrence A. Donehower,et al.  The somatic genomic landscape of chromophobe renal cell carcinoma. , 2014, Cancer cell.

[4]  C. Sander,et al.  Genome-wide analysis of non-coding regulatory mutations in cancer , 2014, Nature Genetics.

[5]  Benjamin J. Raphael,et al.  Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin , 2014, Cell.

[6]  Lovelace J. Luquette,et al.  Diverse Mechanisms of Somatic Structural Variations in Human Cancer Genomes , 2013, Cell.

[7]  Cesare Furlanello,et al.  A promoter-level mammalian expression atlas , 2015 .

[8]  K. Hemminki,et al.  TERT promoter mutations in cancer development. , 2014, Current opinion in genetics & development.

[9]  W. Linehan,et al.  Germline PTEN mutation Cowden syndrome: an underappreciated form of hereditary kidney cancer. , 2013, The Journal of urology.

[10]  Joshua M. Stuart,et al.  The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.

[11]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[12]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.

[13]  The Cancer Genome Atlas Research Network COMPREHENSIVE MOLECULAR CHARACTERIZATION OF CLEAR CELL RENAL CELL CARCINOMA , 2013, Nature.

[14]  Lovelace J. Luquette,et al.  Diverse Mechanisms of Somatic Structural Variations in Human Cancer Genomes , 2013, Cell.

[15]  Peter W. Laird,et al.  Interplay between the Cancer Genome and Epigenome , 2013, Cell.

[16]  G. Stephanopoulos,et al.  In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. , 2013, Cell metabolism.

[17]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[18]  H. Axelson,et al.  Kidney cancer. , 2013, Seminars in cancer biology.

[19]  Sirong Chen,et al.  Dual-Tracer PET/CT in Renal Angiomyolipoma and Subtypes of Renal Cell Carcinoma , 2012, Clinical nuclear medicine.

[20]  David Piquemal,et al.  Of Mice and Men: Divergence of Gene Expression Patterns in Kidney , 2012, PloS one.

[21]  Lynda Chin,et al.  Spectrum of somatic mitochondrial mutations in five cancers , 2012, Proceedings of the National Academy of Sciences.

[22]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[23]  A. Børresen-Dale,et al.  Mutational Processes Molding the Genomes of 21 Breast Cancers , 2012, Cell.

[24]  P. Ward,et al.  Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. , 2012, Cancer cell.

[25]  Vladimir Valera Romero,et al.  The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels. , 2011, Cancer cell.

[26]  P. Russo,et al.  Chromophobe Renal Cell Carcinoma: A Clinicopathologic Study of 203 Tumors in 200 Patients With Primary Resection at a Single Institution , 2011, The American journal of surgical pathology.

[27]  Ximing J. Yang,et al.  Birt-Hogg-Dubé renal tumors are genetically distinct from other renal neoplasias and are associated with up-regulation of mitochondrial gene expression , 2010, BMC Medical Genomics.

[28]  W. Linehan,et al.  The genetic basis of kidney cancer: a metabolic disease , 2010, Nature Reviews Urology.

[29]  Gary D Bader,et al.  International network of cancer genome projects , 2010, Nature.

[30]  J. Brooks,et al.  CD 9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma , 2009, BMC clinical pathology.

[31]  S. Grigoryev,et al.  Rearrangement of upstream sequences of the hTERT gene during cellular immortalization , 2009, Genes, chromosomes & cancer.

[32]  S. Naylor,et al.  A heteroplasmic, not homoplasmic, mitochondrial DNA mutation promotes tumorigenesis via alteration in reactive oxygen species generation and apoptosis. , 2009, Human molecular genetics.

[33]  Paolo Vineis,et al.  Sequence variants at the TERT-CLPTM1L locus associate with many cancer types , 2009, Nature Genetics.

[34]  H. Moch,et al.  Chromophobe Renal Cell Carcinoma: Histomorphologic Characteristics and Evaluation of Conventional Pathologic Prognostic Parameters in 145 Cases , 2008, The American journal of surgical pathology.

[35]  D. Meierhofer,et al.  Loss of Complex I due to Mitochondrial DNA Mutations in Renal Oncocytoma , 2008, Clinical Cancer Research.

[36]  E. Bonora,et al.  Clonal expansion of mutated mitochondrial DNA is associated with tumor formation and complex I deficiency in the benign renal oncocytoma. , 2008, Human molecular genetics.

[37]  Derek Y. Chiang,et al.  Characterizing the cancer genome in lung adenocarcinoma , 2007, Nature.

[38]  S. Prasad,et al.  Segmental disorders of the nephron: histopathological and imaging perspective. , 2007, The British journal of radiology.

[39]  S. Richard,et al.  Mutations in BHD and TP53 genes, but not in HNF1β gene, in a large series of sporadic chromophobe renal cell carcinoma , 2007, British Journal of Cancer.

[40]  S. Richard,et al.  Mutations in BHD and TP53 genes, but not in HNF1β gene, in a large series of sporadic chromophobe renal cell carcinoma , 2006, British Journal of Cancer.

[41]  P. Khavari,et al.  Use of human tissue to assess the oncogenic activity of melanoma-associated mutations , 2005, Nature Genetics.

[42]  A. Nagy,et al.  Lack of mutation of the folliculin gene in sporadic chromophobe renal cell carcinoma and renal oncocytoma , 2004, International journal of cancer.

[43]  K. Pfeiffer,et al.  Mitochondrial complex I is deficient in renal oncocytomas. , 2003, Carcinogenesis.

[44]  Mahul B. Amin,et al.  Prognostic Impact of Histologic Subtyping of Adult Renal Epithelial Neoplasms: An Experience of 405 Cases , 2002, The American journal of surgical pathology.

[45]  W. Linehan,et al.  Birt-Hogg-Dubé syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. , 2001, American journal of human genetics.

[46]  S. Tickoo,et al.  Ultrastructural Observations on Mitochondria and Microvesicles in Renal Oncocytoma, Chromophobe Renal Cell Carcinoma, and Eosinophilic Variant of Conventional (Clear Cell) Renal Cell Carcinoma , 2000, The American journal of surgical pathology.

[47]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[48]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[49]  B. Delahunt,et al.  Classification of renal cell carcinoma , 1997, Cancer.

[50]  G. Hofhaus,et al.  Efficient selection and characterization of mutants of a human cell line which are defective in mitochondrial DNA-encoded subunits of respiratory NADH dehydrogenase , 1995, Molecular and cellular biology.

[51]  E. Schröck,et al.  Specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridization. , 1994, The American journal of pathology.

[52]  S. Störkel,et al.  Human chromophobe cell renal carcinoma , 1985, Virchows Archiv. B, Cell pathology including molecular pathology.

[53]  D. Schadendorf,et al.  Highly Recurrent TERT Promoter Mutations in Human Melanoma , 2022 .